Kepler Cheuvreux Suisse SA Invests $1.23 Million in IQVIA Holdings Inc. $IQV

Kepler Cheuvreux Suisse SA acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, Holdings Channel reports. The fund acquired 5,454 shares of the medical research company’s stock, valued at approximately $1,229,000.

Several other institutional investors and hedge funds also recently modified their holdings of IQV. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA during the fourth quarter worth about $25,000. Physician Wealth Advisors Inc. boosted its position in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the period. International Assets Investment Management LLC acquired a new position in shares of IQVIA during the fourth quarter worth about $27,000. Westside Investment Management Inc. boosted its position in shares of IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the period. Finally, Measured Wealth Private Client Group LLC acquired a new position in shares of IQVIA during the third quarter worth about $30,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Price Performance

NYSE:IQV opened at $173.52 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock’s 50 day moving average price is $170.51 and its two-hundred day moving average price is $200.39. The firm has a market capitalization of $28.96 billion, a price-to-earnings ratio of 21.50, a P/E/G ratio of 1.72 and a beta of 1.18. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 11.5 earnings per share for the current year.

IQVIA announced that its board has initiated a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. UBS Group dropped their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Stifel Nicolaus dropped their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Evercore reiterated an “outperform” rating and set a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. JPMorgan Chase & Co. dropped their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Finally, Mizuho set a $215.00 target price on IQVIA in a report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $225.69.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.